Next Article in Journal
Social Franchising Model as a Scaling Strategy for ICT Reuse: A Case Study of an International Franchise
Next Article in Special Issue
The Effect of Network Structure on Performance in South Korea SMEs: The Moderating Effects of Absorptive Capacity
Previous Article in Journal
A Systematic Review of Smart Real Estate Technology: Drivers of, and Barriers to, the Use of Digital Disruptive Technologies and Online Platforms
Previous Article in Special Issue
The Role of Community-led Governance in Innovation Diffusion: The Case of RFID Waste Pricing System in the Republic of Korea
Article Menu
Issue 9 (September) cover image

Export Article

Open AccessArticle
Sustainability 2018, 10(9), 3143; https://doi.org/10.3390/su10093143

Factors Affecting Pricing in Patent Licensing Contracts in the Biopharmaceutical Industry

1
Graduate School of Health Science Business Convergence, College of Medicine, Chungbuk National University, Cheongju 28644, Korea
2
Department of Computer and Telecommunications Engineering, College of Science and Technology, Yonsei University, 1 Yonseidae-gil, Wonju 26493, Gangwon-do, Korea
*
Authors to whom correspondence should be addressed.
Received: 26 June 2018 / Revised: 31 August 2018 / Accepted: 31 August 2018 / Published: 3 September 2018
Full-Text   |   PDF [510 KB, uploaded 3 September 2018]   |  

Abstract

This paper analyzes factors affecting pricing in patent licensing contracts in the biopharmaceutical industry based on a dataset that includes royalty-related data such as running royalty rate, up-front payment, milestones, and deal value. Data on drug candidates for 11 drug classes is obtained for regression analysis between royalty-related data and multiple input descriptors such as market factors, licensor factors, and licensee factor in order to derive the formula for predicting royalty-related estimates such as royalty rate, up-front payment, milestones, and deal value. Data is gathered from multiple sources including MedTrack and is processed through merging and cleaning. We found that the three most important factors in pricing in patent licensing in the biopharmaceutical industry are CAGR (Compound Annual Growth Rate), PDELR (Previous Deal Experience of Licensor), and AR (Attrition Rate). We found that factors in the formula used to estimate the license fee are totally different by drug class. We found that the three most important factors in the frequency in the formula used to estimate the license fee are PDELR, RnDLR (R&D Costs of Licensor), and PDELE (Previous Deal Experience of Licensee). This study suggests a method of estimating the proper royalty rate, up-front payment, milestones, and deal value of the drug candidates of 11 drug classes by using easily obtained input data. View Full-Text
Keywords: valuation; licensing deal; drug class; royalty rate; up-front fee; milestones; deal value; regression; biotech industry; attrition rate valuation; licensing deal; drug class; royalty rate; up-front fee; milestones; deal value; regression; biotech industry; attrition rate
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Lee, J.H.; Kim, E.; Sung, T.-E.; Shin, K. Factors Affecting Pricing in Patent Licensing Contracts in the Biopharmaceutical Industry. Sustainability 2018, 10, 3143.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Sustainability EISSN 2071-1050 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top